Advanced Therapies 2021 | Addressing remaining barriers to the commercialization of ATMPs

Matthew Durdy, CEO, Cell and Gene Therapy Catapult, London, UK, discusses some of the key remaining barriers to the commercialization of cell and gene therapies. He highlights challenges with patient access to therapies and the way they’re delivered, as well as the importance of enhancing communication with payers in the early stages of product development in order to tackle reimbursement issues. He also notes that increasing manufacturing scale of advanced therapies would lower the cost of goods and facilitate patient access and discusses ongoing work in the UK to better educate academic researchers about the pathway to commercialization. This interview took place at the Advanced Therapies Congress & Expo 2021.